We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication
– This Men's Health Week, Phoenix is addressing misconceptions around erectile dysfunction to raise awareness for treatment and break the social stigma –
TORONTO, June 09, 2025--(BUSINESS WIRE)--For Men's Health Week (June 9 to 15), Phoenix, Canada's leading digital health clinic for men, is raising awareness to break the stigma around erectile dysfunction (ED), a medical condition that affects almost half (49.4%) of Canadian men aged 40 to 88.
ED is a medical condition that prevents the ability to get and maintain an erection sufficient for sexual intercourse, with a range of potential causes that could each contribute to the condition, including age, medications, injury, and lifestyle. Despite its prevalence, Phoenix's survey of more than 1,500 Canadians found that there is a significant lack of awareness around ED and its treatment, likely contributing to stigma surrounding the condition.
CANADIANS UNDERESTIMATE THE REACH OF ED
Despite nearly half of Canadian men over 40 being affected, ED's prevalence is underestimated, driving undue stigma. In fact, almost half of Canadians (45%) think that ED affects less than 40 per cent of men 40+. Twenty-seven per cent of Canadians think it affects less than 30 per cent of men 40+.
While Canadians underestimate the prevalence of ED in middle-aged and older men, many are also unaware that the condition can also impact younger men. The survey found that 64 per cent of Canadians don't know that men aged 35 and younger can experience ED. That percentage grows as you look at younger men, with 71% of Canadians unaware that men aged 18 to 25 can be affected. This common misconception can contribute to the stigma around experiencing ED as a younger man, making it more difficult for those struggling to seek care.
"ED is a medical condition that men of all ages can experience. There shouldn't be anything awkward about it, but there is. We're trying to change that," says Kevin Bache, co-founder and co-CEO of Phoenix. "While it may feel uncomfortable, men need to understand what the condition entails, and not shy away from being proactive in discussing it with a doctor. The sooner you get started, the better your chances are at finding mental and physical relief."
WIDESPREAD MISUNDERSTANDING OF ED MEDICATION
Treatment for ED and its underlying cause can vary greatly depending on a patient's prognosis, however, medication is a common and effective treatment. Despite this fact, Phoenix's survey found 18 per cent of men are unsure if ED is treatable with medication, revealing a lack of awareness that may leave many suffering needlessly.
The data also highlighted a concerning gap in awareness that ED medication requires a prescription. Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED. However, the lack of awareness is most significant among younger Canadians. About three in five Gen Z (59%) don't know that you need a prescription for ED medication: 32 per cent are unsure, and 27 per cent don't think you need a prescription at all.
It is important that Canadians know that ED medication requires a prescription from a medical professional, as they may otherwise be vulnerable to purchasing unauthorized sexual enhancement products sold over the counter, which Health Canada warns could pose serious health risks.
"It's no surprise that people aren't aware of the prevalence of ED – it just doesn't get talked about enough. But the good news is, there are treatment options, and with more openness and awareness, more people can seek support immediately," says Gavin Thompson, co-founder and co-CEO of Phoenix. "We built Phoenix to change that. Our mission is simple: make expert care easy to access – fast, discreet, and doctor-led. We're building a future where men take charge of their health with confidence."
WHAT CANADIANS NEED TO KNOW ABOUT ED
ED can affect men at any age, but it becomes more common as you get older.
ED is more common than you may think, affecting almost half of Canadian men aged 40 to 88.
Many factors can cause ED, including: low levels of testosterone, nervous dysfunction, blood flow complications, medications, medical conditions, lifestyle factors, obesity, diet, drug abuse, smoking, and emotional or psychological complications.
ED is highly treatable, but the first step is consulting a medical professional. Treatment for erectile dysfunction and its underlying cause can vary greatly, making it important to consult a medical professional to receive a diagnosis and devise an effective treatment strategy.
ED medication requires a prescription from a medical professional.
Phoenix is currently available in Ontario, Alberta, British Columbia, Saskatchewan, Manitoba, Nova Scotia, New Brunswick, PEI, and Newfoundland. To learn more about Phoenix's ED support, visit https://www.phoenix.ca/treatments/erectile-dysfunction.
ABOUT PHOENIX
Phoenix is Canada's leading digital health clinic for men, specializing in three areas of treatment – erectile dysfunction, weight loss, and hair loss. The telehealth platform facilitates access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit Phoenix.ca to learn more.
SURVEY METHODOLOGY
These findings are from a survey conducted by Phoenix from May 20th to May 22nd, 2025, among a representative sample of 1509 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/-2.53 percentage points, 19 times out of 20.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609610043/en/
Contacts
MEDIA Anne-Marie TrembleSenior Account Manager, Talk Shop Mediaannemarie@talkshopmedia.com 613-914-3551
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
17 minutes ago
- Gizmodo
The Upsetting Truth About What Wildfire Smoke Does to Your Body
Much of Canada is ablaze again, with more than 200 active wildfires having consumed roughly 10,000 square miles (26,000 square kilometers) since January, the Canadian Interagency Forest Fire Centre reported Thursday, June 5. This escalating situation pumped massive amounts of smoke across the Canada-U.S. border, affecting air quality as far south as Florida, according to the National Oceanic and Atmospheric Administration (NOAA). As climate change lengthens and intensifies wildfire season in many regions across the world, understanding the dangers of smoke exposure is increasingly important. A wave of new research paints a complex picture of how wildfire smoke impacts the body, linking it to startling health outcomes that go far beyond the respiratory system. 'There is an urgent need for research to fully understand the health impacts of wildfire smoke to raise awareness among public and health professionals, as well as to support the development of effective regulations to mitigate the impacts,' Yaguang Wei, assistant professor of environmental medicine at Mount Sinai's Icahn School of Medicine, recently told the Harvard Gazette. Wei is the lead author of a new study, published in May in the journal Epidemiology, which found that wildfire smoke can damage the lungs and heart for up to three months after the fire is out. He and his colleagues linked this 'medium-term' exposure to increased risks of various cardiorespiratory conditions, including heart disease, stroke, high blood pressure, pneumonia, chronic lung disease, and asthma. 'Even brief exposures from smaller fires that last only a few days can lead to long-lasting health effects,' Wei told the Harvard Gazette. Infectious fumes Wildfire smoke is a mixture of gases, air pollutants, water vapor, and fine particulate matter (PM2.5), according to the Environmental Protection Agency (EPA). It contains significant levels of toxic compounds such as polycyclic aromatic hydrocarbons (PAHs) and volatile organic compounds (VOCs), some of which are known carcinogens. Recent studies even suggest that wildfire smoke carries microbial and fungal pathogens. One such study, published in the ISME Journal in 2021, noted that 80% of microbes found in wildfire smoke samples were still viable. While it's still unclear how these organisms survive the extremely high temperatures in wildfires, researchers do have an idea of how they get into the smoke in the first place. George Thompson, a professor of medicine at the University of California, Davis, who was not involved in the study, told Gizmodo that wildfires pull pathogens from the surrounding soil and vegetation as they draw in air. 'The good news is, most of those bacteria and fungi really don't cause infections [in healthy individuals],' Thompson said. 'We're most concerned for our patients whose immune systems have been impacted already,' such as those receiving chemotherapy or recovering from trauma, he added. A 2023 study, however, found evidence to suggest that wildfire smoke could raise infection risk among the general population. The findings, published in The Lancet, Planetary Health, associated California wildfires with an 18% to 22% increase in invasive fungal infections such as valley fever. Thompson pointed out that the study was based on large hospital data, which is 'a great start,' but further research will need to corroborate this link. The brain on fire The most hazardous component of wildfire smoke is not pathogens, but PM2.5. These minuscule particles penetrate deep inside the lungs and wreak havoc on the respiratory system. Previous research has shown that the tiniest, ultrafine particles can pass from the lungs directly into the bloodstream. This can damage blood vessels and trigger harmful inflammation and oxidative stress in various organs, including the brain. Multiple studies have associated wildfire smoke exposure with incidence of dementia. Last year, research published in JAMA Neurology analyzed health data from more than 1.2 million Southern Californians aged 60 and older, and found a significant link between long-term exposure to wildfire-related PM2.5 and a heightened risk of dementia. Specifically, every 1 microgram per cubic meter increase in the three-year average of wildfire PM2.5 raised the odds of a dementia diagnosis by 18%. In comparison, the same increase in PM2.5 from non-wildfire sources was linked to only a 1% greater risk of developing dementia. 'I was expecting for us to see an association between wildfire smoke exposure and dementia,' lead author Holly Elser, an epidemiologist and resident physician in neurology at the University of Pennsylvania, told the Los Angeles Times in 2024. 'But the fact we see so much stronger of an association for wildfire as compared to non-wildfire smoke exposure was kind of surprising.' Psychological fallout Other studies have linked wildfire smoke to adverse psychological outcomes. Research published in JAMA Network Open in April analyzed data on wildfire PM2.5 levels and mental health-related emergency department visits throughout California between July and December 2022—the state's worst wildfire season on record. The study found that wildfire smoke correlated with a significant spike in mental health emergency department visits for up to seven days post-exposure. 'Our study suggests that—in addition to the trauma a wildfire can induce—smoke itself may play a direct role in worsening mental health conditions like depression, anxiety, and mood disorders,' co-author Kari Nadeau, a physician-scientist at the Harvard T.H. Chan School of Public Health, said in a university statement. Questions remain All of this research demonstrates that wildfire smoke is more than just a respiratory hazard. But experts are still in the early stages of unraveling its complex health impacts—particularly in terms of mental health, Angela Yao, a senior scientist with the Environmental Health Services at the B.C. Centre for Disease Control in Canada, told Gizmodo. Many questions remain unanswered, she said. For example, 'How do you disentangle the impact of smoke from the impact of the fire itself?' Future studies will need to investigate these confounding factors. But, 'even with the current evidence that we have—it already gives us confidence that we should take a lot of action,' she added. To protect yourself from the hazards of wildfire smoke, Yao recommended limiting the length and intensity of time spent outdoors. 'The harder you breathe, the more smoke you inhale,' she said. If you must go outside, wearing an N95 mask or a P100 can reduce your smoke exposure, according to the EPA. Keep windows and doors shut to ensure that your indoor air is safe. It's also important to make sure your home's HVAC system is running properly, Yao added. If you don't have one, you can purchase a portable air filter or build your own using a furnace filter and a box fan. As wildfire season becomes increasingly impactful, taking steps to protect yourself and your family from smoke has never been more critical. Experts still have a long way to go towards fully understanding the risks of wildfire exposure, but one thing is clear—these hazards aren't going away any time soon.
Associated Press
an hour ago
- Associated Press
Southwire's Project GIFT® Supports Water Mission With Annual Walk for Water Events Internationally
Throughout the months of April and May, Southwire's Project GIFT® partnered with Water Mission to host Walk for Water events across the company. More than 350 participants volunteered their time to be a part of the events this year, collecting more than $38,000 in support of Water Mission. Walk for Water is a community event that raises awareness and funds for the global water crisis. At the event, participants walk a course that is roughly 2-3 miles, simulating the trek that many people around the world take to get drinking water each day. According to the Water Mission website, two billion people around the world lack access to safe water. The non-profit was founded in 2001 with the goal of ending this crisis by bringing clean, fresh water to those in less fortunate circumstances. 'Walk for Water is one of my favorite events,' said Stefanie Anderson, senior giving back specialist at Southwire. 'Water Mission's goal is so important. Clean water is often something we all take for granted. I always bring my children so that they can learn about the world and know that they that they can have an impact, even if it is small steps.' This spring, Southwire facilities in Bremen, Ind., Denton, Texas, Youngsville, N.C., the West Ga. region, Calgary and Toronto, Canada, and Honduras hosted walks in their communities. The Southwire Honduras team was joined at their event by members of Water Mission's own Honduras-based team. 2025 marks the fourth year that Southwire sites participated in Walk for Water. 'Being a part of this event is something small and doable for our community, but the global impact that it has is tremendous,' said Candice Winters, director of people and culture at Southwire. 'We are giving clean water—which is essential yet taken for granted—to communities that would not otherwise be able to have it. It is such a cool event for an amazing purpose and organization.' Access to clean, safe water transforms lives. Worldwide, millions of people are forced to rely on polluted water sources, exposing them to severe health risks caused by waterborne diseases. Clean water is the first step in paving the way not just for health, but for education and economic growth while helping to break the cycle of poverty. 'It's truly inspiring to see Southwire employees across so many locations unite with one purpose—to walk, raise awareness and help provide access to safe water,' said Heather Fleming, national walk program specialist for Water Mission. 'Their commitment through Walk for Water is making a tangible difference, not just for individuals but for entire communities. Safe water means improved health, the opportunity for children to attend school and the ability for families to thrive. Southwire's partnership is a powerful reminder that when we walk together, we bring lasting change to those who need it most.' Project GIFT's Walk for Water is made possible with the support of many community sponsors including West Georgia Technical College, CDT Construction, University of West Georgia, Medimpact, Heart Wood Products, Cintas, 3:16 Healthcare, RaLin, Tisinger Vance, Phoenix Wood Products and Gradick Communications. To learn more about Southwire's Giving Back activities and strategy, click here. For more Southwire news, visit Visit 3BL Media to see more multimedia and stories from Southwire
Medscape
2 hours ago
- Medscape
Perspective Shifts on the Use of MS Meds During Pregnancy
PHOENIX — Two new datasets support the use of potent disease-modifying therapies (DMTs) during pregnancy in women with active multiple sclerosis (MS), reinforcing a growing shift toward treatment when the potential benefit to the mother outweighs the risks. Both studies — one involving the anti-CD20 monoclonal antibody ofatumumab and the other the integrin receptor antagonist natalizumab — are observational, but they provide a foundation for taking a proactive rather than reactive approach to treating pregnant women with active MS, said Riley M. Bove, MD, associate professor of neurology, University of California San Francisco. Bove emphasized that a 'we-don't-know' approach is no longer acceptable when counseling pregnant women with active disease. As first author of the ofatumumab study — presented on May 29 at Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting— she followed up with a lecture the next day, explaining that evidence is now available to guide treatment decisions. Relevant Data While significant knowledge gaps remain about the relative risks of DMTs to fetal development and pregnancy outcomes, it is well established that women with active disease 'will be harmed if we do not help,' Bove said. She and others now believe that the available data, even if observational, are relevant and useful in guiding decisions that affect both maternal and fetal health. The new data on ofatumumab and natalizumab offer a clear example. In an ongoing registry, ofatumumab exposure has been documented in 669 pregnancies. Of these, 221 were reported prior to 2023, allowing for assessment of both short- and long-term outcomes. In most cases (87%), exposure occurred during the first trimester. Adverse outcomes were reported, including spontaneous abortions in 12.6% of cases, preterm births in 9.6%, and minor congenital malformations in two infants (< 1%). However, these rates are 'in line with the background rates observed in the general population,' Bove noted. She emphasized that such data are important when weighing treatment decisions against the known risks of active disease, which can lead to irreversible brain injury in the mother. The natalizumab data, presented as a late-breaking abstract at CMSC on May 30, reflected 16 years of experience at a single center. Tracking began in 2008, when two pregnancies were identified in women already receiving natalizumab. Through 2024, no increased risk for adverse pregnancy outcomes was observed, while natalizumab treatment was associated with meaningful improvements in MS disease control. A total of 58 pregnancies in 43 women have been tracked at the Rocky Mountain MS Clinic in Salt Lake City, according to Katrina Bawden, FNP-C, a nurse practitioner who has been involved since the registry began. Reevaluating Natalizumab She noted that outcomes were analyzed in women who discontinued natalizumab after learning they were pregnant as well as those who continued treatment into the third trimester. Among the 38 pregnancies in which natalizumab was stopped, 13 women experienced clinical relapses, and four others showed new lesions on MRI. In contrast, among the 20 pregnancies where treatment was continued, there were no relapses and no MRI evidence of disease activity. Pregnancy complications were observed, including one fetal malformation and 10 miscarriages, but Bawden noted that these figures — like those in the ofatumumab registry — are consistent with background rates. 'Of the three fetal deaths, all occurred in those who discontinued natalizumab,' she said. She noted that all 10 of the women who miscarried had healthy term full term deliveries in a subsequent pregnancy while remaining on natalizumab. Compared to the start of the tracking period, Bawden said the data have prompted clinicians at her clinic to reevaluate the benefit-risk balance of using natalizumab during pregnancy. 'Women at the Rocky Mountain MS Clinic who become pregnant while treated with natalizumab, using shared decision-making, are now given the option of continuing natalizumab every 8 weeks throughout pregnancy with the last dose scheduled at 34 weeks' gestation,' Bawden said. 'Illogical Guidance' Caring for pregnant women with MS is a complex challenge, given the incomplete information available. However, Bove — co-author of a 2024 paper on practical considerations for weighing the risks and benefits of DMT use during pregnancy — said that strictly following drug labeling is not helpful in guiding clinical decisions. She noted that current recommendations are inconsistent across drug classes, vary between the FDA and the European Medicines Agency, and often fail to reflect the latest science — resulting in guidance that is ultimately 'illogical.' Moreover, labeling continues to evolve, and pregnancy-related use of DMTs remains a dynamic area, with new data — such as the recent studies presented at CMSC — shaping clinical strategies. Bove emphasized that it is the clinician's responsibility to stay informed as the evidence develops, in order to support shared decision-making. This includes staying up to date on when to treat active disease during pregnancy, when to restart therapy if it was paused, and how to weigh the benefit-risk profile of DMTs for women who choose to breastfeed. When making MS treatment decisions during pregnancy, the adage 'first, do no harm' has traditionally focused on fetal risk. But Bove pointed out that withholding treatment may, in many cases, pose greater harm to the mother, underscoring the need for a balanced discussion that considers risks to both mother and fetus.
